The iNKT-Treg axis in GVHD control

In this issue of Blood, DeFilipp et al 1 report the results of a phase 2b clinical trial with RGI-2001, testing a promising new principle for preventing acute graft-versus-host disease (GVHD).The potential of allogeneic hematopoietic cell transplantation (allo-HCT) to cure hematological malignancies via graftversus-leukemia (GVL) effect is hampered by GVHD.Acute GVHD (aGVHD) is characterized by proliferation of alloreactive donor T cells leading to severe tissue damage of the target organs liver, gut, and skin.